HEMOGLOBIN INDUCED VASOACTIVITY AND RENAL INJURY

血红蛋白引起的血管活性和肾损伤

• 批准号: 2230769
• 负责人: WILFRED LIEBERTHAL
• 金额: $ 33.22万
• 依托单位: BOSTON MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-08-01 至 1998-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2230769
• 关键词: blood toxicology; endothelin; free radical scavengers; hemodynamics; hemorrhagic shock; kidney circulation; kidney circulation disorder; laboratory rat; leukocyte adhesion molecules; nitric oxide; protein purification; renal failure; renal ischemia /hypoxia; tissue /cell culture; vasoconstriction; vasomotion

Our application is focused on the concern that purification and protein modification of stroma free hemoglobin (SFH) will not prevent toxicity in animals or humans. We will examine the hypothesis that SFH will cause prolonged systemic and intrarenal vasoconstriction persisting after the oxyhemoglobin is metabolized. We also will examine the hypothesis that both unmodified and modified preparations of SFH have the potential to cause acute renal failure (ARF) in two distinct settings: a. We hypothesize that SFH will exacerbate renal injury when administered shortly after established renal failure has been caused by a period of renal ischemia. b. We hypothesize that the SFH will cause "de novo" ARF (in the absence of established renal injury) when administered in large, "therapeutic" doses following hemorrhagic shock. Our specific aims are: 1. To examine and compare the mechanisms of vasoconstriction induced by unmodified and modified SFH. We will examine the mechanism by which oxyhemoglobin inhibits nitric oxide mediated vasorelaxation to determine whether protein modification is likely to reduce this cause of vasoconstriction associated with unmodified SFH We will examine the role of endothelin release in SFH-associated vasoconstriction. 2. To test the hypothesis that SFH will induce neutrophil mediated endothelial injury. We will examine the effects of unmodified and modified forms of SFH and its metabolite hemin on neutrophil-endothelial cell adhesion and neutrophil-induced endothelial injury. The pathogenetic mechanisms involved in the SFH induced neutrophil-adhesion interactions will be elucidated. 3. To examine and compare the extent to which unmodified and modified SFH exacerbates underlying established ischemic renal injury. 4. To examine the extent to which unmodified and modified SFH cause de novo ARF after the administration of large amounts of SFH to hypovolemic animals. We will examine our hypothesis that renal failure will be induced days after the administration of SFH to hypotensive rats resulting from the combined effects of a) prolonged intrarenal vasoconstriction b) the accumulation of toxic metabolites (hemin and free iron) in the renal parenchyma and c) neutrophil-induced endothelial injury.

我们的应用重点关注纯化和蛋白质